Improving the use of long-acting injectable HIV prevention

Optimizing implementation of long-acting injectable PrEP

NIH-funded research Medical College of Wisconsin · NIH-10924590

This study is looking at how to make it easier for doctors to offer a new HIV prevention shot that you get every eight weeks, especially for Black men and transgender women who are at higher risk, so that more people can access this helpful treatment.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionMedical College of Wisconsin NIH-funded
Lab location1 site (Milwaukee, United States)
Project IDNIH-10924590 on NIH RePORTER

What this research studies

This research focuses on enhancing the implementation of long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention, which is administered via an intramuscular injection every eight weeks. The study aims to identify barriers to prescribing this innovative treatment, particularly among healthcare providers, and to understand how it can be effectively integrated into clinical practice. By addressing these challenges, the research seeks to improve access to LAI-PrEP for populations at higher risk of HIV, including Black cisgender men and transgender women. The approach involves collaboration with communities and healthcare facilities to ensure that the treatment meets the needs of those it aims to protect.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals at high risk for HIV, particularly Black cisgender men and transgender women who have sex with men.

Not a fit: Patients who are not at risk for HIV or those who do not have access to healthcare facilities offering LAI-PrEP may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could significantly increase the availability and use of LAI-PrEP, leading to reduced HIV incidence among vulnerable populations.

How similar studies have performed: Other research has shown promise in improving HIV prevention strategies, but the specific implementation of LAI-PrEP is relatively novel and requires further exploration.

Where this research is happening

Milwaukee, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome Virus
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.